Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 8, 2023 7:00 AM EDT1H 2023 Revenue Growth of 16% at CER to $180.8M
Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER
EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q 2023
Reducing 2023 Non-GAAP Operating Expense Guidance to $330M-$350M
Non-GAAP Profitability Projected in 2H 2023
Conference Call... More
